首页> 外文期刊>Clinica chimica acta: International journal of clinical chemistry and applied molecular biology >A novel monoclonal antibody to fibrin monomer and soluble fibrin for the detection of soluble fibrin in plasma.
【24h】

A novel monoclonal antibody to fibrin monomer and soluble fibrin for the detection of soluble fibrin in plasma.

机译:一种针对血纤蛋白单体和可溶性血纤蛋白的新型单克隆抗体,用于检测血浆中的可溶性血纤蛋白。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Soluble fibrin (SF), composed of fibrin monomer (FM) and fibrinogen, is well known to exist in the circulating blood derived from patients with thrombotic diseases, and its quantification is useful to get some information on the state and degree of intravascular coagulation. However, there was no convenient method for the determination of SF. METHODS: We prepared a novel monoclonal antibody (MoAb) (F405) to FM and SF using desAA-fibrin as the immunogen in the presence of anti-polymerant peptide (Gly-Pro-Arg-Pro, GPRP), and the characterization of the F405 was performed by Western blotting analysis and an enzyme-linked immunosorbent assay (ELISA). We also tried to detect SF in human plasma using an ELISA involving the immobilized F405 and horseradish peroxidase (POD)-labeled anti-fibrinogen polyclonal antibody. RESULTS: The antibody reacted with the fibrin degradation products fragments X, Y and E, but not with fibrinogen or its fragments X, Y, D and E, or the fibrin D-dimer. The epitope recognized by F405 appeared to be the alpha-chain N-terminal region exposed upon removal of the A peptide from the Aalpha-chain because F405 was found to bind to the alpha-chain N-terminal oligo-peptide of fibrin (GPRVVERHQ). Since F405 reacted not only with FM in the presence of GPRP peptide, but also with the SF complex prepared by the addition of thrombin-treated FM to human fibrinogen, we attempted to detect SF in human plasma using ELISA. The analytical range of this method was 1-300 microg/ml. The assay detection limit was < 0.5 microg/ml, and the results of intra- and inter-assay precision studies indicated that this method is accurate and yields reproducible results (< 9.4% and < 10%, respectively). When 56 samples of plasma from patients with disseminated intravascular coagulation (DIC) and 117 control samples from healthy individuals were tested, elevated levels of SF complex were detected in the DIC samples: the mean +/- S.D. of the SF concentration in the DIC and control samples were 63.4 +/- 65.3 microg/ml and 1.9 +/- 1.0 microg/ml, respectively. CONCLUSIONS: The ELISA using F405 is useful for the diagnosis of DIC.
机译:背景:可溶性血纤蛋白(SF)由血纤蛋白单体(FM)和血纤蛋白原组成,众所周知存在于血栓性疾病患者的循环血液中,其定量分析有助于获得有关血管内状态和程度的一些信息凝结。但是,目前尚无简便的方法测定SF。方法:我们在抗聚合肽(Gly-Pro-Arg-Pro,GPRP)存在的情况下,使用desAA-纤维蛋白作为免疫原,制备了针对FM和SF的新型单克隆抗体(MoAb)(F405),并对其进行了表征通过蛋白质印迹分析和酶联免疫吸附测定(ELISA)进行F405。我们还尝试使用包含固定的F405和辣根过氧化物酶(POD)标记的抗纤维蛋白原多克隆抗体的ELISA检测人血浆中的SF。结果:该抗体与纤维蛋白降解产物片段X,Y和E反应,但不与纤维蛋白原或其片段X,Y,D和E或纤维蛋白D-二聚体反应。 F405识别的表位似乎是从Aalpha链上去除A肽后暴露的α链N末端区域,因为发现F405与纤维蛋白的α链N末端寡肽(GPRVVERHQ)结合。由于F405不仅在GPRP肽存在下与FM反应,而且与通过在人血纤蛋白原中添加凝血酶处理的FM而制备的SF复合物发生反应,因此我们尝试使用ELISA检测人血浆中的SF。该方法的分析范围是1-300μg/ ml。测定检测限为<0.5 microg / ml,测定内和测定间精密度研究的结果表明,该方法准确且可重现(分别<9.4%和<10%)。当测试了56例弥散性血管内凝血(DIC)患者的血浆样品和117例健康个体的对照样品时,在DIC样品中检测到SF复合物水平升高:平均值+/- S.D. DIC和对照样品中的SF浓度分别为63.4 +/- 65.3微克/毫升和1.9 +/- 1.0微克/毫升。结论:F405 ELISA法可用于DIC的诊断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号